Event Type: Q2 FY27 Earnings Conference Call held on November 5, 2026
Management Participants: Dr. Satakarni Makkapati (CEO of Aurobindo Biosimilars, Vaccines and Peptide Businesses & Director), Mr. Yugandhar Puvvala (CEO of Eugia Pharma Specialties Limited), Mr. Swami Iyer (CEO, Aurobindo Pharma, USA), Mr. V. Muralidharan (CEO, Europe Formulations Business), Mr. S. Subramanian (CFO), Mr. Varun Mali (Investor Relations and Corporate Communications)
Financial Period Discussed: Second quarter and half year ended September 30, 2026 (Q2 FY27)
Key Financial Highlights: Revenue of ₹10,263 crores (24% YoY growth), Operating EBITDA of ₹2,156 crores (28% YoY growth) with margin of 21%, Profit After Tax of ₹1,124 crores, Formulation revenue of ₹9,102 crores (24% YoY), API revenue of ₹1,162 crores (21% YoY), US revenue of ₹4,555 crores ($477 million, 25% YoY), Europe revenue of €288 million (18% constant currency growth), Growth markets revenue of ₹1,026 crores ($107 million, 16% YoY), ARV formulation revenue of $38 million
Strategic Updates: Completed acquisition of Lannett strengthening US presence in complex and controlled substances; A1 Biochem acquisition for integrated small molecule CRDMO business; Launch of ADQUEY (first NDA product for atopic dermatitis) with dedicated dermatology business unit; Launch of generic Advair and approval of generic QVAR in respiratory segment; Raleigh unit received VAI classification supporting regulatory pathway for transdermal, dermal and respiratory products
Operational Metrics: Launched 10 products in US, filed 7 ANDAs, received 12 final approvals; Gross margin of 61.2% vs 59.7% YoY; R&D expenditure of ₹376 crores; Capital expenditure of $89 million; Strong cash flow of $146 million; Net cash position of $189 million; Average finance cost of 4.9%
Guidance: FY27 double-digit revenue growth, EBITDA margins north of 21%, absolute EBITDA in excess of ₹8,000 crores; Expect to expand EBITDA margin to upwards of 22% in FY28
Compliance: Transcript being uploaded to company website at https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-calltranscripts/
Additional Notes Section
The document includes the full transcript of the Q2 FY27 earnings conference call
The transcript contains detailed Q&A session with analysts covering various aspects of business performance and outlook
Management provided updates on facility utilization, integration progress, and future growth drivers across different business segments
